Concurrent Treatment of Cardiovascular Disease in Peritoneal Dialysis (PD) patients. Multi-center Randomized Clinical Study with Aldosterone blockade (spironolactone) and Angiotensin Receptor Blocker (ARB) or Angiotensin-Converting-Enzyme Inhibitor (ACEI).

Not Applicable

• Conditions: End-Stage Renal Disease (ESRD) and Cardio-Vascular Disease (CVD)

• Registration Number: JPRN-UMIN000000492
• Lead Sponsor: agoya University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2006-10-01
• Study Completion: 2010-07-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 160

Inclusion Criteria

Not provided

Exclusion Criteria

Should be excluded even if one of them would be positive; Patients under 18, older than 80. Patients with anemia whose Hb is less than 9 g/dl. Patients treated for more than 5 years after initiation of dialysis. Patients with heart failure of NYHA III, IV. Patients with pregnancy or the suspected. Patients treated with acid-base fluid dialysis.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Parameters of CVD, occurrence and/or augmentation of the other complications in peritoneal dialysis (PD) patients

Secondary Outcome Measures

Name	Time	Method
residual renal functional examination, peritoneal functional examination